Search

Your search keyword '"Gutierrez, Maria J."' showing total 2 results
Start Over Author "Gutierrez, Maria J." Publisher oxford university press / usa
2 results on '"Gutierrez, Maria J."'

1. Atazanavir Modestly Increases Plasma Levels of Raltegravir in Healthy Subjects.

Author

Iwamoto, Marian, Wenning, Larissa A., Mistry, Goutam C., Petry, Amelia S., Liou, Sarah Y., Ghosh, Kaylan, Breidinger, Sheila, Azrolan, Neal, Gutierrez, Maria J., Bridson, William E., Stone, Julie A., Gottesdiener, Keith M., and Wagner, John A.

Subjects
*DRUG efficacy, *CLINICAL drug trials, *GLUCURONOSYLTRANSFERASE, *AIDS treatment, *PLASMA oscillations, *ANTIRETROVIRAL agents, *HIV infections, *THERAPEUTICS, *PHARMACOKINETICS, *PHARMACOLOGY
Abstract

Raltegravir is an HIV integrase inhibitor that is metabolized through glucuronidation by uridine diphosphate glucuronosyltransferase 1A1, and its use is anticipated in combination with atazanavir (a uridine diphosphate glucuronosyltransferase 1A1 inhibitor). Two pharmacokinetic studies of healthy subjects assessed the effect of multiple-dose atazanavir or ritonavir-boosted atazanavir on raltegravir levels in plasma. Atazanavir and atazanavir plus ritonavir modestly increase plasma levels of raltegravir. [ABSTRACT FROM AUTHOR]

Published
2008
Full Text
View/download PDF

2. Pharmacokinetics and Safety of Single, Multiple, and Loading Doses of Fusidic Acid in Healthy Subjects.

Author

Still, J. Gordon, Clark, Kay, Degenhardt, Thorsten P., Scott, Drusilla, Fernandes, Prabhavathi, and Gutierrez, Maria J.

Subjects
*SKIN disease treatment, *ANTIBIOTICS, *DRUG metabolism, *PLACEBOS, *CHEMICAL kinetics
Abstract

A phase 1 trial of fusidic acid (CEM-102), an oral fusidane class antibiotic under development for treatment of gram-positive acute bacterial skin and skin structure infections, evaluating pharmacokinetics and safety is described. A randomized, double-blinded, placebo-controlled, dose escalation study was conducted in healthy adult subjects in the fasting state. Plasma exposure after multiple doses was higher than for single doses, indicating accumulation. Loading doses designed to optimize pharmacodynamic effects were well tolerated and achieved near-steady state concentrations of CEM-102 at 24 h. CEM-102 was safe and generally well tolerated at all single, multiple, and loading doses administered. [ABSTRACT FROM PUBLISHER]

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results